PMID- 35243827
OWN - NLM
STAT- MEDLINE
DCOM- 20220517
LR  - 20230802
IS  - 2398-9238 (Electronic)
IS  - 2398-9238 (Linking)
VI  - 5
IP  - 3
DP  - 2022 May
TI  - Simvastatin is associated with superior lipid and glycaemic control to 
      atorvastatin and reduced levels of incident Type 2 diabetes, in men and women, in 
      the UK Biobank.
PG  - e00326
LID - 10.1002/edm2.326 [doi]
LID - e00326
AB  - INTRODUCTION: Cardiovascular disease (CVD) is the leading cause of mortality in 
      people with Type 2 diabetes mellitus (T2DM). Statins reduce low-density 
      lipoproteins and positively affect CVD outcomes. Statin type and dose have 
      differential effects on glycaemia and risk of incident T2DM; however, the impact 
      of gender, and of individual drugs within the statin class, remains unclear. AIM: 
      To compare effects of simvastatin and atorvastatin on lipid and glycaemic control 
      in men and women with and without T2DM, and their association with incident T2DM. 
      METHODS: The effect of simvastatin and atorvastatin on lipid and glycaemic 
      control was assessed in the T2DM DiaStrat cohort. Prescribed medications, gender, 
      age, BMI, diabetes duration, blood lipid profile and HbA1c were extracted from 
      Electronic Care Record, and compared in men and women prescribed simvastatin and 
      atorvastatin. Analyses were replicated in the UKBiobank in those with and without 
      T2DM. The association of simvastatin and atorvastatin with incident T2DM was also 
      investigated in the UKBiobank. Cohorts where matched for age, BMI and diabetes 
      duration in men and women, in the UKBioBank analysis, where possible. RESULTS: 
      Simvastatin was associated with better LDL (1.6 +/- 0.6 vs 2.1 +/- 0.9 mmol/L, 
      p < .01) and total cholesterol (3.6 +/- 0.7 vs 4.2 +/- 1.0 mmol/L, p < .05), and 
      glycaemic control (62 +/- 17 vs 67 +/- 19 mmol/mol, p < .059) than atorvastatin 
      specifically in women in the DiaStrat cohort. In the UKBiobank, both men and 
      women prescribed simvastatin had better LDL (Women: 2.6 +/- 0.6 vs 
      2.6 +/- 0.7 mmol/L, p < .05; Men: 2.4 +/- 0.6 vs 2.4 +/- 0.6, p < .01) and glycaemic 
      control (Women:54 +/- 14 vs 56 +/- 15mmol/mol, p < .05; Men, 54 +/- 14 vs 
      55 +/- 15 mmol/mol, p < .01) than those prescribed atorvastatin. Simvastatin was 
      also associated with reduced risk of incident T2DM in both men and women 
      (p < .0001) in the UKBiobank. CONCLUSIONS: Simvastatin is associated with 
      superior lipid and glycaemic control to atorvastatin in those with and without 
      T2DM, and with fewer incident T2DM cases. Given the importance of lipid and 
      glycaemic control in preventing secondary complications of T2DM, these findings 
      may help inform prescribing practices.
CI  - (c) 2022 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley 
      & Sons Ltd.
FAU - English, Andrew R
AU  - English AR
AUID- ORCID: 0000-0003-1232-5585
AD  - Northern Ireland Centre for Stratified Medicine, School of Biomedical Sciences, 
      C-TRIC, Altnagelvin Hospital, Ulster University, Derry~Londonderry, UK.
FAU - Prasad, Bodhayan
AU  - Prasad B
AUID- ORCID: 0000-0002-7383-2460
AD  - Northern Ireland Centre for Stratified Medicine, School of Biomedical Sciences, 
      C-TRIC, Altnagelvin Hospital, Ulster University, Derry~Londonderry, UK.
FAU - McGuigan, Declan H
AU  - McGuigan DH
AD  - Northern Ireland Centre for Stratified Medicine, School of Biomedical Sciences, 
      C-TRIC, Altnagelvin Hospital, Ulster University, Derry~Londonderry, UK.
FAU - Horigan, Geraldine
AU  - Horigan G
AUID- ORCID: 0000-0002-3841-3252
AD  - Northern Ireland Centre for Stratified Medicine, School of Biomedical Sciences, 
      C-TRIC, Altnagelvin Hospital, Ulster University, Derry~Londonderry, UK.
FAU - O'Kane, Maurice
AU  - O'Kane M
AD  - Clinical Chemistry Laboratory, Altnagelvin Hospital, Derry~Londonderry, UK.
AD  - Centre for Personalised Medicine: Clinical Decision Making and Patient Safety, 
      C-TRIC, Altnagelvin Hospital, Londonderry, UK.
FAU - Bjourson, Anthony J
AU  - Bjourson AJ
AD  - Northern Ireland Centre for Stratified Medicine, School of Biomedical Sciences, 
      C-TRIC, Altnagelvin Hospital, Ulster University, Derry~Londonderry, UK.
FAU - Shukla, Priyank
AU  - Shukla P
AD  - Northern Ireland Centre for Stratified Medicine, School of Biomedical Sciences, 
      C-TRIC, Altnagelvin Hospital, Ulster University, Derry~Londonderry, UK.
FAU - Kelly, Catriona
AU  - Kelly C
AD  - Northern Ireland Centre for Stratified Medicine, School of Biomedical Sciences, 
      C-TRIC, Altnagelvin Hospital, Ulster University, Derry~Londonderry, UK.
FAU - McClean, Paula L
AU  - McClean PL
AD  - Northern Ireland Centre for Stratified Medicine, School of Biomedical Sciences, 
      C-TRIC, Altnagelvin Hospital, Ulster University, Derry~Londonderry, UK.
LA  - eng
GR  - MC_PC_17228/MRC_/Medical Research Council/United Kingdom
GR  - MC_QA137853/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220304
PL  - England
TA  - Endocrinol Diabetes Metab
JT  - Endocrinology, diabetes & metabolism
JID - 101732442
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Lipids)
RN  - A0JWA85V8F (Atorvastatin)
RN  - AGG2FN16EV (Simvastatin)
SB  - IM
MH  - Atorvastatin/therapeutic use
MH  - Biological Specimen Banks
MH  - *Cardiovascular Diseases/epidemiology/etiology/prevention & control
MH  - *Diabetes Mellitus, Type 2/drug therapy/epidemiology/prevention & control
MH  - Female
MH  - Glycemic Control
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Lipids/therapeutic use
MH  - Male
MH  - Simvastatin/therapeutic use
MH  - United Kingdom/epidemiology
PMC - PMC9094470
OTO - NOTNLM
OT  - HbA1c
OT  - UK Biobank
OT  - gender differences
OT  - glycaemic control
OT  - lipid control
OT  - statin
OT  - type 2 diabetes
COIS- The authors have no conflicts of interests to declare.
EDAT- 2022/03/05 06:00
MHDA- 2022/05/18 06:00
PMCR- 2022/03/04
CRDT- 2022/03/04 05:48
PHST- 2022/01/31 00:00 [revised]
PHST- 2021/07/05 00:00 [received]
PHST- 2022/02/02 00:00 [accepted]
PHST- 2022/03/05 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
PHST- 2022/03/04 05:48 [entrez]
PHST- 2022/03/04 00:00 [pmc-release]
AID - EDM2326 [pii]
AID - 10.1002/edm2.326 [doi]
PST - ppublish
SO  - Endocrinol Diabetes Metab. 2022 May;5(3):e00326. doi: 10.1002/edm2.326. Epub 2022 
      Mar 4.